Skip to main content
48°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Akili, Inc. - Common Stock
(NQ:
AKLI
)
0.2433
+0.0033 (+1.37%)
Streaming Delayed Price
Updated: 10:04 AM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Akili, Inc. - Common Stock
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Akili, Inc.
Via
Business Wire
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
February 27, 2024
From
PureTech Health plc
Via
Business Wire
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
February 26, 2024
From
Akili, Inc.
Via
Business Wire
Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates
February 21, 2024
From
Akili, Inc.
Via
Business Wire
EndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17
December 18, 2023
From
Akili, Inc.
Via
Business Wire
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Akili, Inc.
Via
Business Wire
Akili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ET
October 19, 2023
From
Akili, Inc.
Via
Business Wire
Employees with ADHD Aren’t Reaching Their Full Potential at Work, Akili Study Finds
October 12, 2023
From
Akili, Inc.
Via
Business Wire
Akili Announces Leadership Transition
October 06, 2023
From
Akili, Inc.
Via
Business Wire
Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD
September 21, 2023
From
Akili, Inc.
Via
Business Wire
Akili Announces Business Transformation, Focusing on Non-prescription Model
September 13, 2023
From
Akili, Inc.
Via
Business Wire
Akili Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
Akili, Inc.
Via
Business Wire
Akili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ET
July 10, 2023
From
Akili, Inc.
Via
Business Wire
Akili Releases EndeavorOTCTM Video Game Treatment to Improve Attention in Adults with ADHD
June 07, 2023
From
Akili, Inc.
Via
Business Wire
Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress
May 31, 2023
From
Akili, Inc.
Via
Business Wire
Akili Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
From
Akili, Inc.
Via
Business Wire
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
May 04, 2023
From
PureTech Health plc
Via
Business Wire
Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
May 03, 2023
From
Akili, Inc.
Via
Business Wire
Akili to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 11 at 4:30 p.m. ET
April 13, 2023
From
Akili, Inc.
Via
Business Wire
Akili Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 07, 2023
From
Akili, Inc.
Via
Business Wire
Akili to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, March 7 at 4:30 p.m. ET
February 06, 2023
From
Akili, Inc.
Via
Business Wire
Akili to Participate in the Cowen 43rd Annual Health Care Conference
February 02, 2023
From
Akili, Inc.
Via
Business Wire
Akili to Champion Digital Therapeutics in Conjunction with J.P. Morgan Healthcare Conference
January 06, 2023
From
Akili, Inc.
Via
Business Wire
Pivotal Trial of EndeavorRxⓇ in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes
January 05, 2023
From
Akili, Inc.
Via
Business Wire
Akili Announces ADHD Expert Dr. Scott Kollins to Join as Chief Medical Officer
December 01, 2022
From
Akili, Inc.
Via
Business Wire
Akili Reports Third Quarter 2022 Financial Results and Company Update
November 10, 2022
From
Akili, Inc.
Via
Business Wire
Financial Industry Veteran Mary Hentges Joins Akili’s Board of Directors
October 27, 2022
From
Akili, Inc.
Via
Business Wire
Akili to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 10 at 4:30 p.m. ET
October 19, 2022
From
Akili, Inc.
Via
Business Wire
Akili Launches EndeavorRx® Expedition - A Direct-to-Patient Product Registry
September 21, 2022
From
Akili, Inc.
Via
Business Wire
Akili to Participate in LifeSci Partners HealthTech Symposium
September 19, 2022
From
Akili, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.